Reported Earnings • May 11
First quarter 2026 earnings released: NT$0.21 loss per share (vs NT$0.28 loss in 1Q 2025) First quarter 2026 results: NT$0.21 loss per share (improved from NT$0.28 loss in 1Q 2025). Revenue: NT$796.9m (flat on 1Q 2025). Net loss: NT$9.61m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 11
Full year 2025 earnings released: NT$1.63 loss per share (vs NT$1.09 loss in FY 2024) Full year 2025 results: NT$1.63 loss per share (further deteriorated from NT$1.09 loss in FY 2024). Revenue: NT$3.22b (down 1.4% from FY 2024). Net loss: NT$73.2m (loss widened 55% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. お知らせ • Feb 24
We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026 We Can Medicines Co., Ltd., Annual General Meeting, May 29, 2026. Location: no,335, jui kuang rd., neihu district, taipei city Taiwan Reported Earnings • Nov 08
Third quarter 2025 earnings released: NT$0.58 loss per share (vs NT$0.47 loss in 3Q 2024) Third quarter 2025 results: NT$0.58 loss per share (further deteriorated from NT$0.47 loss in 3Q 2024). Revenue: NT$789.5m (down 2.8% from 3Q 2024). Net loss: NT$26.2m (loss widened 26% from 3Q 2024). Reported Earnings • Aug 09
Second quarter 2025 earnings released: NT$0.15 loss per share (vs NT$0.078 loss in 2Q 2024) Second quarter 2025 results: NT$0.15 loss per share (further deteriorated from NT$0.078 loss in 2Q 2024). Revenue: NT$816.8m (flat on 2Q 2024). Net loss: NT$6.66m (loss widened 102% from 2Q 2024). Reported Earnings • May 14
First quarter 2025 earnings released: NT$0.28 loss per share (vs NT$0.27 profit in 1Q 2024) First quarter 2025 results: NT$0.28 loss per share (down from NT$0.27 profit in 1Q 2024). Revenue: NT$797.9m (down 2.5% from 1Q 2024). Net loss: NT$12.4m (down 215% from profit in 1Q 2024). Reported Earnings • Mar 15
Full year 2024 earnings released: NT$1.09 loss per share (vs NT$0.37 profit in FY 2023) Full year 2024 results: NT$1.09 loss per share (down from NT$0.37 profit in FY 2023). Revenue: NT$3.27b (up 4.7% from FY 2023). Net loss: NT$47.2m (down 419% from profit in FY 2023). お知らせ • Feb 27
We Can Medicines Co., Ltd., Annual General Meeting, Jun 11, 2025 We Can Medicines Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,12, chou tzu st., neihu district, taipei city Taiwan Reported Earnings • Nov 17
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: NT$812.6m (up 4.9% from 3Q 2023). Net loss: NT$20.9m (loss widened 419% from 3Q 2023). Reported Earnings • Aug 17
Second quarter 2024 earnings: EPS misses analyst expectations Second quarter 2024 results: NT$0.08 loss per share (improved from NT$0.16 loss in 2Q 2023). Revenue: NT$823.9m (up 7.7% from 2Q 2023). Net loss: NT$3.30m (loss narrowed 48% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.16 in 1Q 2023) First quarter 2024 results: EPS: NT$0.27 (up from NT$0.16 in 1Q 2023). Revenue: NT$818.1m (up 6.5% from 1Q 2023). Net income: NT$10.8m (up 67% from 1Q 2023). Profit margin: 1.3% (up from 0.8% in 1Q 2023). New Risk • Apr 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 5.4% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (NT$3.19b market cap, or US$97.8m). New Risk • Mar 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Revenue has declined by 5.4% over the past year. Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Market cap is less than US$100m (NT$3.20b market cap, or US$99.9m). お知らせ • Mar 16
We Can Medicines Co., Ltd., Annual General Meeting, May 27, 2024 We Can Medicines Co., Ltd., Annual General Meeting, May 27, 2024. Reported Earnings • Mar 05
Full year 2023 earnings released: EPS: NT$0.37 (vs NT$2.50 in FY 2022) Full year 2023 results: EPS: NT$0.37 (down from NT$2.50 in FY 2022). Revenue: NT$3.12b (down 5.4% from FY 2022). Net income: NT$14.8m (down 85% from FY 2022). Profit margin: 0.5% (down from 3.0% in FY 2022). The decrease in margin was driven by lower revenue. New Risk • Jan 23
New major risk - Revenue and earnings growth Revenue has declined by 2.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 2.9% over the past year. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.5% net profit margin). 